Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Being bearish but also bullish on Europe Inc

Wed, 07th Dec 2022 11:22

STOXX 600 down 0.5%

*

U.S. banks warn of recession

*

GSK rallies as Zantac lawsuits dismissed

*

U.S. stock futures slip

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

BEING BEARISH BUT ALSO BULLISH ON EUROPE INC (1116 GMT)

Jefferies goes straight to point to highlight how different each European country equity market is, which in turns means the dispersion of returns in the region is going to vary widely.

"One size doesn't fit all," says Sean Darby, one of the bank's global equity strategists.

Darby and team in fact are bullish on countries like France and the UK, modestly bullish on Germany, while at the same time, they're bearish on Poland and modestly so for Italy.

"European bourses are far from homogenous, so the dispersion of equity returns in 2023 will be quite wide," they say.

Bringing all together though, they see gains for the Euro STOXX betting that lead indicators will bottom out in the first half of 2023, followed by earnings revisions with a 3-month lag.

"There is room for the index to climb by ~12% as interest rates are likely to peak in 1Q23. This would leave the index trading on 480," they write.

EUROPEANS JUST LOVE GOOGLE (1039 GMT)

Growth stocks have been all the rage over the past few years, at least until late 2020, when it became apparent that the world economy was recovering and inflation was - at least at that point - ticking up at a comfortable pace. But once rates started rising and inflation began to rip higher, value stocks, which are more closely linked to the underlying economy, reemerged as a top pick. This year, European value stocks, which include the likes of energy, natural resources and autos, have gained 1.7%, compared with a drop of nearly 14% in growth stocks and an 11% fall in the broader STOXX.

In terms of what would-be European investors are interested in, the answer is clear, according to data from retail investing company CMC Markets. "Google" is the most searched-for growth stock in the region, topping the charts in 27 countries, with Meta's "Facebook" a close second, coming out on top in 20 countries. The number of searches varies depending on the population. Germany is the country with the highest number of searches a month and "Google" is the most popular, with 149,000 searches. The Netherlands is second, with 115,000 searches. Ukraine is the country with the most searches for "Facebook", with 107,000 searches a month, followed by the UK and France, with 87,000 and 86,000 searches, respectively.

"Google and Facebook are dominating as the most popular growth stocks across Europe. Both of these companies have a huge influence on the market, and the media, which is why many Europeans are looking to invest in them," Michael Hewson, chief market analyst at CMC Markets said.

FORZA ITALIA IN EARLY EUROPE (0915 GMT)

Italy may not have made it to the soccer World Cup, but Milan blue-chips are leading the way this morning, as European equities trade in a sea of red so far. The FTSE MIB is up 0.6%, by far the best performing index in the region, compared with a 0.1% loss in the broader STOXX 600 index, and well beyond Stockholm's 0.5% loss. Utility company ENEL is leading its sector higher and is up 1.5%, making it one of the biggest positive weights on the STOXX and lender UniCredit is up 1.8%.

But today belongs to the pharma and biotech sector, which is the standout gainer, up 1% thanks to a surge in shares of UK drugmaker GSK following a U.S. ruling that dismissed thousands of lawsuits claiming that over-the-counter heartburn medication Zantac causes cancer. The stock rose as much as 15% earlier on and, with a 10% gain, is on track for its largest one-day rise since 1998. French rival Sanofi, which is also part of the suit, is up 5.7%. All the drugmakers involved denied Zantac caused cancer.

HAT-TRICK (0755 GMT)

While European shares ended lower for the third straight session on Tuesday, spooked by recession worries, another hat-trick dominated the World Cup a few hours later.

Three goals by Portugal's 21-year-old Goncalo Ramos against Spain in his first World Cup sent his side through to the quarter-finals for the first time in 16 years. And a 3-0 shootout win by Morocco against former champions Spain meant that Morocco became the first Arab nation ever to qualify for the tournament's quarter-finals.

In the arena of European stocks, there seem to be little excitement for risky assets on Wednesday, with Asian equities trading rangebound after U.S. stocks again suffered losses as markets gradually factor in sharper interest rates hikes.

For the euro zone, commentary by officials is hinting at a peak in rates but anaemic growth and stubbornly high inflation are haunting investors.

ECB policymaker Constantinos Herodotou said on Tuesday that interest rates will go up again but are now "very near" their neutral level.

Markets will focus on industrial output data due from Germany, while euro zone third-quarter GDP and employment numbers, and UK house prices are among the other economic indicators for the day.

Euro zone government bond yields dropped for the first time in three days on Tuesday in the run-up to a raft of major central bank decisions next week.

A Reuters poll of market strategists expect the dollar to rebound against most currencies over the coming months, with the growing threat of recession in the U.S. and elsewhere keeping it firm in 2023 through safe-haven flows.

On Tuesday, top bankers from JPMorgan Chase & Co, Bank of America and Goldman Sachs warned of a recession next year, as inflation threatens consumer demand.

On the corporate front, Airbus gave up a numerical forecast for jet deliveries and a date for its key production goal but retained its financial targets as it limped towards the end of a year battered by disruptions in factories and supply chains.

And British Prime Minister Rishi Sunak's government said it would ease restrictions on building onshore wind farms, heading off a revolt by his party's lawmakers who had demanded they should be permitted with local support.

Key developments that could influence markets on Wednesday:

Economic data: Germany Oct industrial production, Euro zone Q3 GDP, employment (final), UK Nov Halifax house prices

Speakers: ECB's Philip Lane, Elizabeth McCaul and Fabio Panetta

More News
24 Feb 2023 15:10

First Zantac cancer risk trial in Calif. postponed five months

Feb 23 (Reuters) - The first scheduled trial over claims that GSK Plc's heartburn drug Zantac caused cancer, which had been set to begin Monday, has been postponed by five months.

Read more
16 Feb 2023 23:17

Judge weighs key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - Lawyers for a man who alleges he developed bladder cancer after taking GSK Plc's heartburn drug Zantac urged a California judge on Thursday to allow expert testimony linking the drug to the illness at an upcoming trial.

Read more
16 Feb 2023 19:38

Judge to weigh key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - GSK Plc is expected to urge a California judge on Thursday to limit what expert testimony jurors can hear in the first trial over claims that the company's heartburn drug Zantac caused cancer.

Read more
13 Feb 2023 17:19

European shares rise as defence stocks rally, focus on U.S. inflation data

STOXX 600 ends up 0.9%

*

Read more
3 Feb 2023 17:27

European shares log weekly gains, UK's blue-chip index hits record high

STOXX 600 up 0.3%, logs gains for second straight week

*

Read more
3 Feb 2023 11:49

Sanofi forecasts moderate profit growth on Dupixent demand

Sees "low single digit" percentage core EPS growth, FX adjusted

*

Read more
31 Jan 2023 12:26

Share buybacks in Europe as significant as in U.S.

STOXX 600 down around 1%

*

Read more
31 Jan 2023 11:30

Banks: six reasons to be overweight

STOXX 600 down 1%

*

Read more
31 Jan 2023 09:15

STOXX slides

STOXX 600 down 0.5%

*

Read more
31 Jan 2023 07:36

European shares seen lower

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPEAN SHARES SEEN LOWER (0730 GMT)

Read more
31 Jan 2023 06:56

Mind the gap

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

MIND THE GAP (0656 GMT)

Read more
30 Jan 2023 20:27

Drugmakers prevail in dispute over U.S. discount drug program

Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.

Read more
30 Jan 2023 17:42

Drugmakers prevail in dispute over U.S. discount drug program

Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.

Read more
4 Jan 2023 10:51

Sanofi sees decision on Zantac dispute with Boehringer in Q1 at earliest

Arbitration decision initially expected by end of 2022

*

Read more
12 Dec 2022 21:46

Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal

Dec 12 (Reuters) - Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in the sector this year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.